Drugmaker Allergan said on Tuesday it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP, for $2.9 billion in cash, bringing the number of deals it has made this year to an even dozen.
LifeCell makes regenerative tissue products that are commonly used in breast reconstruction procedures and complex hernia surgeries to provide soft tissue support. The products will support Allergan’s portfolio of medical aesthetics, breast implants and tissue expanders, the company said.
Allergan chief executive Brent Saunders has described the company’s acquisition strategy as being one of “stepping stones.” Allergan’s deal to sell itself last year to Pfizer for $160 billion was dropped due to a change in tax law.
Allergan, best known for its Botox product, said LifeCell’s 2016 sales are expected to be $450 million and grow at a mid-single digit rate. It expects the deal to close in the first half of 2017.
Dublin-based Allergan, which was created through the combination of Actavis and Allergan, earlier this year sold its generics business to Teva Pharmaceutical Industries, freeing up cash for deals.Allergan has agreed to 12 deals this year, including the $1.7 billion acquisition of Tobira Therapeutics, maker of an experimental treatment for fatty liver disease, and $639 million acquiring Vitae, maker of an experimental drug to treat psoriasis.
Source: Reuters via Fortune
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.